BWell Science


BWell Antibiotic can treat and kill ALL bacteria it has been tested on.  It can also kill virus and fungus even though it is an antibiotic.  It was registered as an OTC Topical antibiotic using the FDA Monograph pathway, a fast track, inexpensive method of bringing new drugs to the marketplace. However, the drug can do so much more than a simple topical antibiotic.

The mechanism of action is what makes this possible.  Incredible amounts of the medication penetrates the cell walls of the organisms (doesn't matter whether it is a bacteria, fungus, or virus such as COVID-19), the efflux pumps which are designed to pump out poisons become overwhelmed because they can not handle the massive influx of the medication.  So the organism (bacteria, fungus or virus) simply bursts and dies.

In the early stages of research and development of the drug, back in 2011-2012, we tested it on patients with both Herpes Simplex I and II virus.  We had over 90% success rates in all patients.  The drug has also been used as a preventative against Influenza Virus by having patients swab the inside of their nostrils with a q-tip dipped in the medication.  Once again, the mechanism of action overwhelms the virus and patients recover from their symptoms very quickly.  Rubbing BWell Antibiotic on the tips of one’s fingers and hands will also reduce the spread of the virus.  These same methods can be used for COVID-19.

For infections that are outside the scope that the FDA approved it for, physicians can use it as an off label drug.  Off-label use is the use of pharmaceutical drugs for an unapproved indication or in an unapproved age group, dosage, or route of administration. The ability to prescribe drugs for uses beyond the officially approved indications is commonly used to good effect by healthcare providers.

In these unprecedented times where the entire world is being ravaged by the COVID-19 virus, we must find novel ways to treat this disease. I truly believe that Vitastem can play a very important role in fighting COVID-19 as an "off label" drug.

Please feel free to share this information to interested parties.


Dr. Christopher Otiko, MS, DPM

Inventor of BWell

CEO, ViaDerma, Inc.